Evidence map›Paper›PMID 26039055›Full record

ArticlePloS one2015

RNA Interference-Guided Targeting of Hepatitis C Virus Replication with Antisense Locked Nucleic Acid-Based Oligonucleotides Containing 8-oxo-dG Modifications.

Margit Mutso, Andrei Nikonov, Arno Pihlak, Eva Žusinaite, Liane Viru, Anastasia Selyutina, Tõnu Reintamm, Merike Kelve, Mart Saarma, Mati Karelson and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Preparing for the next viral threat with broad-spectrum antivirals.The Journal of clinical investigation · 2023
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. HCV core protein represses the apoptosis and improves the autophagy of human hepatocytes.International journal of clinical and experimental medicine · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Margit MutsoInstitute of Technology, University of Tartu, Tartu, Estonia; GeneCode, Ltd., Tallinn, Estonia.
Andrei NikonovInstitute of Technology, University of Tartu, Tartu, Estonia; GeneCode, Ltd., Tallinn, Estonia.
Arno PihlakGeneCode, Ltd., Tallinn, Estonia.
Eva ŽusinaiteInstitute of Technology, University of Tartu, Tartu, Estonia; GeneCode, Ltd., Tallinn, Estonia.
Liane ViruInstitute of Technology, University of Tartu, Tartu, Estonia; GeneCode, Ltd., Tallinn, Estonia.
Anastasia SelyutinaInstitute of Technology, University of Tartu, Tartu, Estonia.
Tõnu ReintammGeneCode, Ltd., Tallinn, Estonia; Department of Gene Technology, Tallinn University of Technology, Tallinn, Estonia.
Merike KelveGeneCode, Ltd., Tallinn, Estonia; Department of Gene Technology, Tallinn University of Technology, Tallinn, Estonia.
Mart SaarmaInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Mati KarelsonGeneCode, Ltd., Tallinn, Estonia; Institute of Chemistry, University of Tartu, Tartu, Estonia.
Andres MeritsInstitute of Technology, University of Tartu, Tartu, Estonia.
University of Tartu · EETallinn University of Technology · EEUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inhibitory potency of an antisense oligonucleotide depends critically on its design and the accessibility of its target site. Here, we used an RNA interference-guided approach to select antisense oligonucleotide target sites in the coding region of the highly structured hepatitis C virus (HCV) RNA genome. We modified the conventional design of an antisense oligonucleotide containing locked nucleic acid (LNA) residues at its termini (LNA/DNA gapmer) by inserting 8-oxo-2'-deoxyguanosine (8-oxo-dG) residues into the central DNA region. Obtained compounds, designed with the aim to analyze the effects of 8-oxo-dG modifications on the antisense oligonucleotides, displayed a unique set of properties. Compared to conventional LNA/DNA gapmers, the melting temperatures of the duplexes formed by modified LNA/DNA gapmers and DNA or RNA targets were reduced by approximately 1.6-3.3°C per modification. Comparative transfection studies showed that small interfering RNA was the most potent HCV RNA replication inhibitor (effective concentration 50 (EC50): 0.13 nM), whereas isosequential standard and modified LNA/DNA gapmers were approximately 50-fold less efficient (EC50: 5.5 and 7.1 nM, respectively). However, the presence of 8-oxo-dG residues led to a more complete suppression of HCV replication in transfected cells. These modifications did not affect the efficiency of RNase H cleavage of antisense oligonucleotide:RNA duplexes but did alter specificity, triggering the appearance of multiple cleavage products. Moreover, the incorporation of 8-oxo-dG residues increased the stability of antisense oligonucleotides of different configurations in human serum.

Indexed as

Genome, Viral8-Hydroxy-2'-DeoxyguanosineBase PairingCell Line, TumorDeoxyguanosineHepacivirusHepatocytesHumansMolecular Targeted TherapyOligonucleotidesOligonucleotides, AntisenseRNA CleavageRNA InterferenceRNA, Small InterferingRNA StabilityRNA, Viral8-Hydroxy-2'-DeoxyguanosineDeoxyguanosinelocked nucleic acidOligonucleotidesOligonucleotides, AntisenseRNA, Small InterferingRNA, Viral

Identifiers

PMID26039055
PMCPMC4454572
OpenAlexW2274663911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.